430 related articles for article (PubMed ID: 37527180)
21. Treating hyperphosphatemia - current and advancing drugs.
Ketteler M; Liangos O; Biggar PH
Expert Opin Pharmacother; 2016 Oct; 17(14):1873-9. PubMed ID: 27643443
[TBL] [Abstract][Full Text] [Related]
22. Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.
Sekercioglu N; Thabane L; Díaz Martínez JP; Nesrallah G; Longo CJ; Busse JW; Akhtar-Danesh N; Agarwal A; Al-Khalifah R; Iorio A; Guyatt GH
PLoS One; 2016; 11(6):e0156891. PubMed ID: 27276077
[TBL] [Abstract][Full Text] [Related]
23. State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective.
Scialla JJ; Kendrick J; Uribarri J; Kovesdy CP; Gutiérrez OM; Jimenez EY; Kramer HJ
Am J Kidney Dis; 2021 Jan; 77(1):132-141. PubMed ID: 32771650
[TBL] [Abstract][Full Text] [Related]
24. An update on phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a review of safety profiles.
Ogata H; Takeshima A; Ito H
Expert Opin Drug Saf; 2022 Jul; 21(7):947-955. PubMed ID: 35180026
[TBL] [Abstract][Full Text] [Related]
25. The Rising Risk of Chronic Kidney Disease (CKD) and How it is Dealt with: A Review of Current and Potential Phosphate Binders (PB).
Gosik R; Danel K
Mini Rev Med Chem; 2021; 21(19):3052-3061. PubMed ID: 34137362
[TBL] [Abstract][Full Text] [Related]
26. Sevelamer and the bone-vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation.
Brandenburg VM; Jahnen-Dechent W; Ketteler M
Kidney Int Suppl; 2009 Dec; (114):S26-33. PubMed ID: 19946324
[TBL] [Abstract][Full Text] [Related]
27. Effects of phosphate binders in moderate CKD.
Block GA; Wheeler DC; Persky MS; Kestenbaum B; Ketteler M; Spiegel DM; Allison MA; Asplin J; Smits G; Hoofnagle AN; Kooienga L; Thadhani R; Mannstadt M; Wolf M; Chertow GM
J Am Soc Nephrol; 2012 Aug; 23(8):1407-15. PubMed ID: 22822075
[TBL] [Abstract][Full Text] [Related]
28. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
Toussaint ND; Pedagogos E; Lioufas NM; Elder GJ; Pascoe EM; Badve SV; Valks A; Block GA; Boudville N; Cameron JD; Campbell KL; Chen SSM; Faull RJ; Holt SG; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Hooi LS; Narayan O; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Hawley CM;
J Am Soc Nephrol; 2020 Nov; 31(11):2653-2666. PubMed ID: 32917784
[TBL] [Abstract][Full Text] [Related]
29. Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease.
Rastogi A
Ther Adv Cardiovasc Dis; 2013 Dec; 7(6):322-42. PubMed ID: 24327730
[TBL] [Abstract][Full Text] [Related]
30. Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients.
Zeng Q; Zhong Y; Yu X
Ren Fail; 2023 Dec; 45(1):2210230. PubMed ID: 37272189
[TBL] [Abstract][Full Text] [Related]
31. Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects.
Frazão JM; Adragão T
Nephron Clin Pract; 2012; 120(2):c108-19. PubMed ID: 22555359
[TBL] [Abstract][Full Text] [Related]
32. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
Lioufas N; Toussaint ND; Pedagogos E; Elder G; Badve SV; Pascoe E; Valks A; Hawley C;
BMJ Open; 2019 Feb; 9(2):e024382. PubMed ID: 30796122
[TBL] [Abstract][Full Text] [Related]
33. Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
Phan O; Maillard M; Malluche HH; Stehle JC; Funk F; Burnier M
Biomed Res Int; 2015; 2015():515606. PubMed ID: 26221597
[TBL] [Abstract][Full Text] [Related]
34. Next-generation phosphate binders: focus on iron-based binders.
Nastou D; Fernández-Fernández B; Elewa U; González-Espinoza L; González-Parra E; Sanchez-Niño MD; Ortiz A
Drugs; 2014 Jun; 74(8):863-77. PubMed ID: 24848754
[TBL] [Abstract][Full Text] [Related]
35. [Strategies aiming to control hyperphosphatemia in chronic kidney disease].
Ureña Torres PA
Nephrol Ther; 2017 Apr; 13 Suppl 1():S95-S101. PubMed ID: 28577750
[TBL] [Abstract][Full Text] [Related]
36. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.
Locatelli F; Del Vecchio L; Violo L; Pontoriero G
Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470
[TBL] [Abstract][Full Text] [Related]
37. Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease.
Cernaro V; Calimeri S; Laudani A; Santoro D
Ther Clin Risk Manag; 2020; 16():871-880. PubMed ID: 32982259
[TBL] [Abstract][Full Text] [Related]
38. [Current approaches in the treatment of hyperphosphatemia in chronic kidney disease].
Matuszkiewicz-Rowińska J; Kościelska M
Wiad Lek; 2017; 70(6 pt 2):1161-1165. PubMed ID: 29533905
[TBL] [Abstract][Full Text] [Related]
39. Phosphate binders in moderate chronic kidney disease: where do we stand?
Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
[TBL] [Abstract][Full Text] [Related]
40. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]